Previous 10 | Next 10 |
Pfizer and BioNTech's announcement that, based on preliminary data, their COVID-19 vaccine is 90% effective and an emergency use authorization ((EUA)) is only weeks away has led to downward pressure on some of the second tier developers. If all goes according to plan, deployment could start b...
The FDA has signed-off investigational new drug application for Phase 1 study with Sorrento's ([[SRNE]] -13.5%) intravenous ((IV)) COVI-AMG (STI-2020) for the treatment of COVID-19 patients with mild symptoms and a separate study to evaluate safety and pharmacokinetics in ...
IND filing today for STI-2020 (COVI-AMG™) for the treatment of COVID-19 in patients with mild symptoms and a separate safety and pharmacokinetic study in healthy volunteers. These initial trials are expected to be followed by pivotal trials with a goal of potentially receiving ...
Sorrento currently presents a wide multitude of candidate drugs to combat COVID-19. Due to this huge Covid-19 program, the share price has skyrocketed in recent months, although since the August peak the stock price has been deflating to reach around $7. The problem here is that t...
The stock market rewards patience. Parking your money in securities with solid prospects and a strong competitive advantage is a great strategy for yielding substantial results over longer periods of time. But for some stocks, doubling in value in just a year is a real possibility. Investor...
The Robinhood 100 has become known as a barometer of millennial investing trends due to its focus on the top 100 stocks owned by users of the Robinhood trading platform. But many of the stock on the list are not great companies. Here are five stocks to avoid: Carnival Corporation (CCL), Inovi...
In an IND-enabling study, intranasal COVI-AMG nAb (STI-2099 or COVI-DROPS TM ) very early on decreased COVID-19 disease severity and shortened the duration of the disease in infected hamsters, and Sorrento is in preparation for IND filings for both intranasal COVI-DROPS nAb (STI...
The ongoing race to make vaccines and therapies for the coronavirus has led to a tremendous amount of speculation in the market. For some stocks, these expectations have merely added fuel to the fire of a strong company's robust returns for shareholders. For others, like Sorrento Therapeu...
Are These The Best Coronavirus Stocks To Buy Now? Coronavirus stocks have been a trending topic to watch in the stock market this year. With the resurgence of coronavirus cases globally, it’s comforting to know Gilead Sciences’ ( GILD Stock Report ) remdesi...
Sorrento Therapeutics (NASDAQ: SRNE) is one of this year's rollercoaster stocks, riding the market crash and the coronavirus product hype train to grow by more than 450% before collapsing to its present level, 130% above its price on Jan. 1. Sorrento's stock is extremely headline-dr...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...